patient subgroup...
ECOG 0 ECOG 1 Hemoglobin concentration < 10g/dl hemoglobin concentration > 10g/dl metastasis (liver ) metastasis (lymph node ) smoker (Current) smoker (Former) smoker (never)
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
mUC - L2 - all population, atezolizumab alone versus Standard of Care (SoC), meta-analysis of study results
Outcome
Relative effect 95%CI
LoD
Trt. better when
I2
k (RCT/OBS)
Bayesian probability
Overall ROB
Publication bias
Degree of certainty
Endpoint importance
Published MA
efficacy endpoints 00 deaths (OS) 0.85 [0.73, 0.99]< 1 0% 1 study (1/-) 98.2 % NA not evaluable crucial - deaths (OS) (extension) 0.82 [0.71, 0.94]< 1 0% 1 study (1/-) 99.7 % NA not evaluable important - progression or deaths (PFS) 0.89 [0.60, 1.32]< 1 0% 1 study (1/-) 71.3 % NA not evaluable important - DOR 0.16 [0.07, 0.35]< 1 0% 1 study (1/-) 100.0 % NA not evaluable non important - objective responses (ORR) 0.99 [0.68, 1.45]> 1 0% 1 study (1/-) 48.5 % NA not evaluable non important - safety endpoints 00 AE (any grade) 0.38 [0.17, 0.88]< 1 0% 1 study (1/-) 98.9 % NA not evaluable non important - AE (grade 3-4) 0.80 [0.62, 1.04]< 1 0% 1 study (1/-) 94.9 % NA not evaluable non important - AE leading to death (grade 5) 0.91 [0.46, 1.79]< 1 0% 1 study (1/-) 61.0 % NA not evaluable non important - AE leading to treatment discontinuation (any grade) 0.37 [0.24, 0.57]< 1 0% 1 study (1/-) 100.0 % NA not evaluable non important - SAE (any grade) 0.92 [0.70, 1.19]< 1 0% 1 study (1/-) 74.4 % NA not evaluable non important - STRAE (any grade) 0.56 [0.40, 0.78]< 1 0% 1 study (1/-) 100.0 % NA not evaluable non important - TRAE (any grade) 0.28 [0.19, 0.40]< 1 0% 1 study (1/-) 100.0 % NA not evaluable non important - TRAE (grade 3-4) 0.33 [0.25, 0.45]< 1 0% 1 study (1/-) 100.0 % NA not evaluable non important - TRAE leading to death (grade 5) 0.42 [0.13, 1.39]< 1 0% 1 study (1/-) 92.2 % NA not evaluable non important - TRAE leading to discontinuation (any grade) 0.22 [0.12, 0.38]< 1 0% 1 study (1/-) 100.0 % NA not evaluable non important - TRAE (grade 3-4) endpoints 00 Anaemia TRAE (grade 3-4) 0.40 [0.18, 0.89]< 1 0% 1 study (1/-) 98.8 % NA not evaluable non important - Asthenia TRAE (grade 3-4) 0.42 [0.18, 0.97]< 1 0% 1 study (1/-) 97.8 % NA not evaluable non important - Constipation TRAE (grade 3-4) 0.02 [0.00, 0.38]< 1 0% 1 study (1/-) 99.5 % NA not evaluable non important - Fatigue TRAE (grade 3-4) 0.37 [0.15, 0.88]< 1 0% 1 study (1/-) 98.7 % NA not evaluable non important - Febrile neutropenia TRAE (grade 3-4) 0.04 [0.00, 0.27]< 1 0% 1 study (1/-) 99.9 % NA not evaluable non important - Neutropenia TRAE (grade 3-4) 0.04 [0.01, 0.15]< 1 0% 1 study (1/-) 100.0 % NA not evaluable non important - Peripheral neuropathy TRAE (grade 3-4) 0.12 [0.01, 0.95]< 1 0% 1 study (1/-) 97.7 % NA not evaluable non important -
LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias;
suggested: nominally statistically significant but without a strict control of overall risk of type 1 error;
inconclusive: not nominally statistically significant;
safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies;
published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE.
Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.